EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?

EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?
5 1 vote
Article Rating

EW Stock Forecast: For the Next 24 hours, the stock price of EW is predicted to trade between $ 115.94 and $ 122.70. The Overall recommendation for next 24 hours is buy.

2 of 3 momentum indicators are positive

EW is trading 2.13% higher at $ 122.12 in the last trading session.

    Metric  
Value
Market Cap
7.6 B
        Share Volume  
6M
    Average Share Volume
2 M
     Forward PE (1year)  
52.91
EW stock forecast

EW Stock Forecast: Momentum Summary

Metric
Indicator
Price
Higher
Technical indicators
Buy
Sentiment
NA

EW Stock Forecast: Performance Chart

1 Day
5 Days
1 month
1 year
2.13%
0.24%
4.35%
42.60%

EW Stock Forecast: Technical Analysis

Analyst
S3
R1
Recommendation
114.52
121.76
Buy
117.37
123.65
Buy

EW Stock Forecast: Latest Videos

Edwards Lifesciences CEO on outlook for 2022: ‘We are just getting started’

EW Stock Forecast: Sentiment Analysis

Day
Positive
Negative
Indicator
Day 7
0%
6%
Negative
Day 1
NA
NA
NA

Also Read: Moderna Stock Forecast

EW Stock Forecast: Latest News and Tweets

vig.io on Twitter: “$EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target. / Twitter”

EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target.

Ew Healthcare Partners Fund 2, Buys 5,050 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

EW Stock Forecast: Company Background

Edward lifesciences is an American based medical technology company. It was founded in the year 1958 in Irvine, California. The company works on Artificial heart valves and hemodynamic monitoring and produces new technologies to treat late cardiovascular diseases. It was founded by an engineer Miles Lowell Edwards.

EW Stock Forecast: Q3 Results

  • Sales increased 15% to 1.3 billion as of on 30th September
  • Increased 15% in TAVR sales
  • Increased in US TAVR sales by 12% and OUS approximately 20%
  • Full year 2021 sales guidance range changed
  • EW reported that TAVR sales are $858 million in this third quarter of the financial year
  • With 7% increase compared to third quarter of the last year surgical structural heart sales were $217 million
  • The adjusted gross profit margin was 76.3% compared to 75.5% in the third quarter of last financial year.
  • Research and development expenses were $238 million by an increase of 22%
  • Free cash flow was $471 million and cash flow from operating activities is $532 million

-Rakesh Atla

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x